A couple of deals in the the last week that are noteworthy.
1. 21 Feb - Merck, one of the world’s largest drugmakers, agreed to buy Seattle-based biotechnology company Immune Design for $300 million in cash.
The deal’s price tag, at $5.85 per share, amounted to a more than 300 percent premium on the stock’s price at the previous day’s close. Shares of the company skyrocketed on the news.
2. AbbVie and Voyager Therapeutics said on 22 Feb they will launch a potentially $1.5 billion-plus gene therapy collaboration—the companies’ second billion-dollar-plus alliance in as many years, with the new partnership focused on treating Parkinson’s disease and other diseases characterized by abnormal accumulation of misfolded alpha-synuclein protein.
Cell Therapy News/Articles, page-251
-
- There are more pages in this discussion • 18,023 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.005(0.36%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $4.391M | 3.156M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 48253 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 32922 | 2 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |